CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
Cytokine Adsorption +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04910893
NCT04910893N/ACompleted
CompareCT.gov

Cytokine Adsorption in Severe, Refractory Septic Shock

University of Zurich·interventional·Posted Jun 2, 2021·Updated Jun 10, 2021

In Brief

A clinical study evaluating Cytokine Adsorption and Standard of Care for Septic Shock and Cytokine Storm. Completed, enrolled 48 participants.

Detailed Summary

Septic shock and the underlying dysregulated inflammatory host-response remain a major contributor to mortality in critically ill patients. Cytokine adsorption represents an attractive approach to the treatment of septic shock. Nevertheless, its effect on circulating cytokine levels, as well as on the course of disease remains largely unassessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeptic Shock, Cytokine Storm
Countries--
CollaboratorsCytoSorbents Europe GmbH

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2, 2021
Enrollment StartNov 27, 2014
Primary CompletionAug 24, 2018
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.1 years ago

Interventions

Cytokine Adsorptiondevice

Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.

Standard of Careother

Standard intensive care of patients suffering septic shock